Joanna Shields, Group CEO: Our Vision

Better treatment for every patient.


Today there are an estimated 9,000 untreated diseases and 300 million people suffer from rare diseases with little hope of effective or life-saving treatment. In an age of unprecedented technological advancement, I believe we are obligated to find ways to treat even the most challenging of diseases. What is more, we must remove economic viability as a barrier to developing the medicines these patients need. I am proud to be part of the team that is tackling these challenges head-on.

I believe our mission is so important because there is now broad understanding that AI and machine learning can play a significant role in finding new uses for existing drugs, as well as finding novel treatments for diseases.

We have brought together remarkable, world-class people from across all of the scientific and tech disciplines, to build an extraordinary integrated platform that represents a game-changing moment for drug discovery and development. The synergies that result when the most exciting minds are combined with powerful experimental and computational tools, fuelled by the understanding of huge quantities of high quality data, are truly extraordinary. Already we are able to deliver innovation and results across the entire value chain from raw data, all the way to creating novel compounds that we can test, refine and deliver to patients.

When asked why we do what we do, at Benevolent we always say “Because It Matters”. And our name speaks for itself.


Joanna Shields
Group CEO, BenevolentAI

Unconventional thinking together with purposeful technology can have an impact on humanity.
— Ken Mulvany, Founder of BenevolentAI, at Slush, 2018